Lawrence Eichenfield - 19 Sep 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: Director
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol: FBRX
Transactions as of: 19 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 20 Sep 2023, 17:49:59 UTC
Previous filing: 12 Jun 2023
Next filing: 07 Jun 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Stock Option (right to buy)	Award	$0	+25,000		$0.000000	25,000	19 Sep 2023	Common Stock	25,000	$0.8000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.

Content

Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.